Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
About 80% of patients with pancreatic adenocarcinoma have aberrant fasting blood glucose at
the time of diagnosis. The consistent association between pancreatic cancer and diabetes
mellitus has long been recognized and even been termed as "chicken and egg". Many reports
have found that pancreatic cancer can result in diabetes, which is called type 3c diabetes.
New-onset diabetes is commonly observed in pancreatic cancer patients and has been considered
as a potential screening sign. Moreover, diabetes has been found as a predictor of poor
outcome in pancreatic cancer.
Pancreatic cancer cells have a strong dependence on glucose and they are well-known for their
sweet teeth. High glucose is associated with impaired immunologic reaction, intolerability to
chemotherapy, radiotherapy and other major treatments, an increased risk of pancreatic
surgery. Given the linkage between pancreatic cancer and diabetes or high blood glucose, a
clinical trial is needed to validate the effect of metformin and insulin on regulating blood
glucose in type 3c diabetes.